Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Mary Weiser-Evans to Lung Neoplasms

This is a "connection" page, showing publications Mary Weiser-Evans has written about Lung Neoplasms.

 
Connection Strength
 
 
 
1.180
 
  1. Weiser-Evans MC, Wang XQ, Amin J, Van Putten V, Choudhary R, Winn RA, Scheinman R, Simpson P, Geraci MW, Nemenoff RA. Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res. 2009 Mar 01; 69(5):1733-8.
    View in: PubMed
    Score: 0.177
  2. Johnson AM, Boland JM, Wrobel J, Klezcko EK, Weiser-Evans M, Hopp K, Heasley L, Clambey ET, Jordan K, Nemenoff RA, Schenk EL. Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment. J Thorac Oncol. 2021 10; 16(10):1694-1704.
    View in: PubMed
    Score: 0.104
  3. Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, Hopp K, Weiser-Evans MCM, Heasley LE, Schenk EL, Clambey ET, Nemenoff RA. Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. J Immunol. 2020 04 15; 204(8):2295-2307.
    View in: PubMed
    Score: 0.096
  4. Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Tumor-intrinsic response to IFN? shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Sci Alliance. 2019 06; 2(3).
    View in: PubMed
    Score: 0.090
  5. Sippel TR, Johnson AM, Li HY, Hanson D, Nguyen TT, Bullock BL, Poczobutt JM, Kwak JW, Kleczko EK, Weiser-Evans MC, Nemenoff RA. Activation of PPAR? in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFß1. Mol Cancer Res. 2019 08; 17(8):1748-1758.
    View in: PubMed
    Score: 0.090
  6. Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, Weiser-Evans MC, Lambris JD, Clambey ET, Thurman JM, Nemenoff RA. Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res. 2018 01 01; 78(1):143-156.
    View in: PubMed
    Score: 0.081
  7. Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res. 2017 09; 5(9):767-777.
    View in: PubMed
    Score: 0.080
  8. Poczobutt JM, De S, Yadav VK, Nguyen TT, Li H, Sippel TR, Weiser-Evans MC, Nemenoff RA. Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer. J Immunol. 2016 Mar 15; 196(6):2847-59.
    View in: PubMed
    Score: 0.072
  9. Poczobutt JM, Nguyen TT, Hanson D, Li H, Sippel TR, Weiser-Evans MC, Gijon M, Murphy RC, Nemenoff RA. Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment. J Immunol. 2016 Jan 15; 196(2):891-901.
    View in: PubMed
    Score: 0.071
  10. Marek LA, Hinz TK, von Mässenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res. 2014 Oct; 12(10):1460-9.
    View in: PubMed
    Score: 0.064
  11. Poczobutt JM, Gijon M, Amin J, Hanson D, Li H, Walker D, Weiser-Evans M, Lu X, Murphy RC, Nemenoff RA. Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment. PLoS One. 2013; 8(11):e79633.
    View in: PubMed
    Score: 0.062
  12. Li H, Sorenson AL, Poczobutt J, Amin J, Joyal T, Sullivan T, Crossno JT, Weiser-Evans MC, Nemenoff RA. Activation of PPAR? in myeloid cells promotes lung cancer progression and metastasis. PLoS One. 2011; 6(12):e28133.
    View in: PubMed
    Score: 0.054
  13. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia. 2010 Mar; 12(3):224-34.
    View in: PubMed
    Score: 0.048
  14. Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia. 2010 Mar; 12(3):244-53.
    View in: PubMed
    Score: 0.048
  15. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila). 2008 Oct; 1(5):349-56.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)